Citations

Clear

3042 citation(s) found for "Kumar, S".

Using the Nose-Perf Scale for Symptom Assessment After Transsphenoidal Approach to the Pituitary Gland
Gomes, Pedro Lança , Jategaonkar, Gaurav, Qu, Jiasong, Miglani, Amar , Bansberg, Stephen F. , Marino, Michael J. , Qu, Jess, Kumar, Nitish , Lal, Devyani

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803768 Get It

Flaps in Clival Reconstruction: Systematic Review
Marino, Michael J. , Gomes, Pedro Lança , Kumar, Nitish , Lal, Devyani , Marks, Lisa

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803615 Get It

Comparison of Two Surgical Approaches and Outcomes for Petroclival Meningiomas: A Single-Surgeon Series of Consecutive Cases
Cohen-Cohen, Salomón , Link, Michael J., Kumar, Rahul

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803226 Get It

Long-Term Outcomes and Complication Prediction after Stereotactic Radiosurgery for Previously Untreated Meningiomas
Brown, Paul D. , Graffeo, Christopher S. , Link, Michael J. , Pollock, Bruce E. , Kumar, Rahul , Carlstrom, Lucas P. , Morshed, Ramin A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803210 Get It

Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis
Shrestha, Bibek , Bhusal, Suzit, Kandel, G, Bastakoti, Sudip, Yadav, Krishna , Yadav, Krishna Kumar

Mayo Clinic

Annals of Medicine & Surgery | February 6, 2025 | Volume: 87 | Issue: 3 | Pages: 1617-1627

10.1097/ms9.0000000000003008 | PMID 40213232 Get It

Background and aims: Traditionally, low molecular weight heparin, such as dalteparin, has been the first-line treatment for cancer-associated venous thromboembolism (VTE). However, recent studies suggest that rivaroxaban, a direct oral anticoagulant, may offer comparable efficacy with the convenience of oral administration. This systematic review and meta-analysis aim to evaluate and compare the efficacy and safety of rivaroxaban versus dalteparin in managing cancer-associated VTE, focusing on recurrence rates, bleeding events, and patient adherence. Methods: This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols guidelines, systematically retrieving data from PubMed and Cochrane databases using structured search terms related to cancer, VTE, and anticoagulation. Data on recurrent VTE, major bleeding, and patient outcomes were extracted. Statistical analyses were performed using a random-effects model to account for heterogeneity. Results: Nine studies were analyzed, encompassing a range of study designs across multiple countries. The findings show no significant difference in major bleeding risk between rivaroxaban and dalteparin (risk ratio: 0.91, P = 0.69), nor in bleeding-related mortality (odds ratio [OR]: 4.00, P = 0.36). Rivaroxaban was associated with a significant reduction in deep vein thrombosis (DVT) recurrence (OR: 0.75, P = 0.04) and a marginally nonsignificant reduction in pulmonary embolism recurrence (OR: 0.73, P = 0.05). Nonsignificant bleeding events were slightly higher with rivaroxaban but did not reach statistical significance. Conclusion: Rivaroxaban presents a viable alternative to dalteparin for treating cancer-associated VTE, showing comparable safety regarding major bleeding and potential efficacy in reducing DVT recurrence. This study supports the potential for more standardized guidelines that include rivaroxaban as a feasible option in cancer-associated VTE management.
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Najia, Mohamad , Jha, Deepak Kumar , Zhang, Cheng , Kubaczka, Caroline , Markel, Arianna , Li, Christopher , Morris, Vivian Gunn, Tompkins, Allison, Hensch, Luca, Qin, Yue , Huang, Yu-Chung , Marunde, Matthew R. , Vaidya, Anup , Gillespie, Zachary B , Shi, Yang , Li, Hu , Daley, George Q. , Najia, Mohamad Ali , Jha, Deepak K , North, Trista E , Keogh, Michael-Christopher , Schlaeger, Thorsten M , Shipp, Margaret Ann , Blainey, Paul C , Daley, George Q , Laurent, Benoît , Li, Christopher, Morris, Vivian, Chapuy, Bjoern , Morse, Michael, Howard, Sarah A. , Domínguez, Daniel

Mayo Clinic

No container title available | February 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.31.635709 | PMID 39975048 Get It

ABSTRACT Genes involved in the regulation of chromatin structure are frequently disrupted in cancer, contributing to an aberrant transcriptome and phenotypic plasticity. Yet, therapeutics targeting mutant forms of chromatin-modifying enzymes have yielded only modest clinical utility, underscoring the difficulty of targeting the epigenomic underpinnings of aberrant gene regulatory networks. Here, we sought to identify novel epigenetic vulnerabilities in diffuse large B-cell lymphoma (DLBCL). Through phenotypic screens and biochemical analysis, we demonstrated that inhibition of the H3K9 demethylases KDM4A and KDM4C elicits potent, subtype-agnostic cytotoxicity by antagonizing transcriptional networks associated with B-cell identity and epigenetically rewiring heterochromatin. KDM4 demethylases associated with the KRAB zinc finger ZNF587, and their enzymatic inhibition led to DNA replication stress and DNA damage-induced cGAS-STING activation. Broad surveys of transcriptional data from patients also revealed KDM4 family dysregulation in several other cancer types. To explore this potential therapeutic avenue, we performed high-throughput small molecule screens with H3K9me3 nucleosome substrates and identified novel KDM4 demethylase inhibitors. AI-guided protein-ligand binding predictions suggested diverse modes of action for various small molecule hits. Our findings underscore the relevance of targeting fundamental transcriptional and epigenetic mechanisms for anti-cancer therapy. HIGHLIGHTS Phenotypic screens identified JIB-04 as a potent anti-cancer agent for multiple subtypes of diffuse large B-cell lymphoma JIB-04 binds and inhibits KDM4 demethylases resulting in epigenomic rewiring of heterochromatin KDM4 demethylases cooperate with KRAB zinc fingers to limit DNA replication stress, and KDM4 inhibition instigates DNA-damage and cGAS-STING activation in several human cancers High-throughput small molecule screens with semi-synthetic nucleosome substrates and AI-guided molecular docking simulations identify novel KDM4 inhibitors
Surgical versus conservative management of spinal cord cavernous malformations: a systematic review and comparative meta-analysis
Llano, Juan P Navarro-Garcia de , Ortega-Ruiz, Omar R. , Ravindran, Krishnan , Kumar, Jeyan S. , Williams, Lindsy N., Bydon, Mohamad , Ríos-Zermeño, Jorge , Ghaith, Abdul Karim , El-Hajj, Victor Gabriel , Greco, Elena, Goyal, Anshit , Tawk, Rabih G.

Mayo Clinic

Journal of Neurosurgery: Spine | January 31, 2025 | Volume: 42 | Issue: 4 | Pages: 509-519

10.3171/2024.10.spine24432 | PMID 39889295 Get It

OBJECTIVE Spinal cord cavernous malformations (SCCMs) are rare vascular malformations with a capricious prognosis. Given the eloquent nature of the spinal cord, considerable surgical morbidity may be encountered. Therefore, conservative management has emerged as a valid alternative, especially for incidental lesions diagnosed on ubiquitous imaging. The aim of this systematic review and meta-analysis was to evaluate the safety and efficacy of surgical versus conservative management of SCCMs. METHODS Following PRISMA guidelines, this study included articles published in full-text form comparing the outcomes following conservative and surgical management of SCCMs. Collected variables included the total number of patients, spine level, resection, myelotomy, follow-up duration, bleeding, motor weakness, pain, bladder and/or bowel dysfunction, and neurological improvement or deterioration after discharge. The primary outcome of interest was long-term functional outcome. RESULTS Eleven articles comprising 515 patients were included, of whom 343 (66.6%) underwent resection and 172 (33.4%) were managed conservatively. Patients who underwent surgery were more likely to have preoperative motor deficits, hemorrhagic episodes, and bladder and/or bowel dysfunction, indicating increased disease severity. Resection was associated with significantly improved long-term functional outcomes (OR 3.27, 95% CI 1.72–6.24) compared with conservative management. There was no significant difference between the two groups regarding odds of long-term clinical deterioration (OR 1.03, 95% CI 0.35–3.03). However, the risk of hemorrhagic episodes during follow-up was higher in the conservative group (17.3%) compared with the surgical group (1.69%). The odds of hemorrhage during follow-up were lower in the surgical group, although not statistically significant (OR 0.24, 95% CI 0.05–1.05). CONCLUSIONS This study highlights that while surgical management of SCCMs is associated with better long-term functional outcomes and reduced risk of recurrent hemorrhage, treatment decisions must be carefully tailored to the individual patient, particularly given the potential risks associated with surgery. Conservative management, although less invasive, carries a nonnegligible risk of hemorrhage during follow-up, warranting close monitoring. These findings parallel management strategies used for brainstem cavernomas, for which surgery is reserved for cases with low surgical risk and worsening neurological symptoms. However, the limitations of current data, including selection bias and heterogeneity in reporting, emphasize the need for a multi-institutional registry to better define the natural history of SCCMs and inform future management strategies.
620: PREVALENCE OF SEPSIS BY PHOENIX CRITERIA IN CHILDREN WITH COVID-19: AN SCCM: VIRUS REGISTRY REPORT
McGarvey, Jeremy , Bansal, Vikas , Boman, Karen , Kumar, Vishakha K. , Tripathi, Sandeep , Montgomery, Vicki , Gharpure, Varsha , Kashyap, Rahul, Walkey, Allan J. , Bansal, Vikas

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001101144.95500.72 Get It

195: UNEXPECTED TWIST: INTESTINAL ISCHEMIA IN AN LVAD RECIPIENT
Yadav, Bipin Kumar , Chaudhary, Ashlesha , Lyle, Melissa , Chaudhary, Sanjay, Yadav, Bipin, Guru, Pramod

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001099444.55205.f4 Get It